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Abstract 23 
Dendritic Cells (DCs) are the most potent antigen presenting cells capable of priming naïve T-24 
cells. Its C-type lectin receptor, DC-SIGN, regulates a wide range of immune functions. Along 25 
with its role in HIV-1 pathogenesis through complement opsonization of the virus, DC-SIGN has 26 
recently emerged as an adaptor for complement protein C1q on the surface of immature DCs via 27 
a trimeric complex involving gC1qR, a receptor for the globular domain of C1q.  Here, we have 28 
examined the nature of interaction between C1q and DC-SIGN in terms of domain localization, 29 
and implications of C1q-DC-SIGN-gC1qR complex formation on HIV-1 transmission. We first 30 
expressed and purified recombinant extracellular domains of DC-SIGN and its homologue 31 
SIGN-R as tetramers comprising of the entire extra cellular domain including the α-helical neck 32 
region, and monomers comprising of the carbohydrate recognition domain only. Direct binding 33 
studies revealed that both DC-SIGN and SIGN-R were able to bind independently to the 34 
recombinant globular head modules ghA, ghB and ghC, with ghB being the preferential binder. 35 
C1q appeared to interact with DC-SIGN or SIGN-R in a manner similar to IgG. Mutational 36 
analysis using single amino acid substitutions within the globular head modules showed that 37 
TyrB175 and LysB136 were critical for the C1q-DC-SIGN/SIGN-R interaction. Competitive studies 38 
revealed that gC1qR and ghB shared overlapping binding sites on DC-SIGN, implying that HIV-39 
1 transmission by DCs could be modulated due to the interplay of gC1qR-C1q with DC-SIGN. 40 
Since C1q, gC1qR and DC-SIGN can individually bind HIV-1, we examined how C1q and 41 
gC1qR modulated HIV-1-DC-SIGN interaction in an infection assay. Here, we report, for the 42 
first time, that C1q suppressed DC-SIGN-mediated transfer of HIV-1 to activated PBMCs, 43 
although the globular head modules did not. The protective effect of C1q was negated by the 44 
addition of gC1qR. In fact, gC1qR enhanced DC-SIGN-mediated HIV-1 transfer, suggesting its 45 
role in HIV-1 pathogenesis. Our results highlight the consequences of multiple innate immune 46 
pattern recognition molecules forming a complex that can modify their functions in a way which 47 
may be advantageous for the pathogen.  48 
 49 
 50 
 51 
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Introduction  52 
Dendritic Cell Specific Intracellular adhesion Grabbing Non Integrin (DC-SIGN) is a C-type 53 
lectin expressed on dendritic cells (DCs) that functions as a pattern recognition receptor (PRR). 54 
It can interact with a range of viral, bacterial and fungal pathogens to primarily promote Th2 55 
responses via activation of the mitogen activated protein kinases Erk1 and Erk2  (1) , leading to 56 
the clearance of pathogens. DC-SIGN also modulates TLR signaling through activating Serine 57 
and Threonine kinase Raf1, which acetylates the NF-κB subunit p65 upon interaction with 58 
various pathogens, such as Mycobacterium tuberculosis, M. leprae, C. albicans, and measles 59 
virus  (2, 3) . Acetylation of p65 and increased IL-10 transcription leads to an enhanced anti-60 
inflammatory cytokine response  (2) . DC-SIGN also mediates DC-T cell interaction via 61 
Intracellular Adhesion Molecule-3 (ICAM-3)  (4) . In addition, DCs can adhere to endothelial 62 
cells expressing high levels of ICAM-2 via DC-SIGN. Further interactions between Lymphocyte 63 
Function-Associated Antigen-1 (LFA-1) and ICAM-1 with ICAM-2–DC-SIGN  (5)  promote 64 
trans-endothelial migration of DCs, allowing them to travel from the blood to the lymphatic 65 
system where they can induce T cell responses. Martinez et al have shown that DC-SIGN 66 
stimulated CD3-activated T cells produce IL-2, which, in turn, enhances T cell differentiation  67 
(6) . DC-SIGN can bind the cell wall component, glycolipid ManLAM of M. tuberculosis, and 68 
inhibit DC maturation through the suppression of TLR-4  (7) . Such a cross-talk between TLRs 69 
and DC-SIGN that generates anti-inflammatory immune response highlights the two faced role 70 
of DC-SIGN in immune regulation.  71 
DC-SIGN can bind to HIV-1 envelope protein gp120 through glycan structures  (8)  and mediate 72 
HIV transmission in cis- and trans- fashion. The cis-mode supports DC-SIGN-mediated viral 73 
internalization and limited replication; in trans-mode, viral particles are endocytosed and 74 
presented to CD4+ cells  (9) . DC-SIGN, thus, allows DCs to carry HIV-1 to the lymph nodes 75 
where interactions between DCs and T cells leads to transmission of the virus to CD4+ T cells, 76 
leading to their infection and eventual depletion  (10) . The Hepatitis C Virus (HCV) envelope 77 
glycoprotein E2 is another viral protein DC-SIGN engages with  (11) . This is achieved through 78 
utilizing its high quality endocytic capability to internalize the viral antigen, leading to the 79 
infection of DCs  (12) .  80 
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Structurally, DC-SIGN is composed of an extracellular domain which exists as a tetramer, 81 
stabilized by an N-terminal α-helical neck region, followed by a Carbohydrate Recognition 82 
Domain (CRD) (8) . Its affinity for N-linked high mannose oligosaccharides is evident through 83 
its ligands HIV-1 gp120 and ICAM-3 being highly glycosylated, indicating that this binding is 84 
mediated through the CRD region  (13, 14) . Studies have shown that the interaction between 85 
gp120 and DC-SIGN triggers a drop in IL-6 production by immature DCs.  In addition to this, 86 
gp120 binding to DC-SIGN has also been shown to suppress the anti-apoptotic activity of Nef 87 
and induce apoptosis in immature DCs  (14) . Thus, HIV pathogenesis heavily relies on the 88 
interplay of molecular mechanisms involving DC-SIGN.  89 
Recently, it has emerged that DC-SIGN interacts with the complement classical pathway 90 
recognition protein, C1q  (15) , in conjunction with its globular head receptor, gC1qR, on the 91 
surface of immature DCs. C1q as well as gC1qR are known to associate with the viral envelope 92 
protein gp41 of HIV-1  (16, 17) . C1q has been shown to interact with gp41 ectodomain via its 93 
globular head (gC1q) domain  (18) , specifically via the A chain  (19) , in a way similar to C1q-94 
IgG interaction  (20, 21) . Similar to IgG, the ability of gp41 to form aggregates  (16)  leads to an 95 
enhanced activation of the C1 complex, as well as the function of gp41 to initiate the classical 96 
pathway on the surface of infected cells in an antibody-independent manner  (22) . The C1q 97 
binding site on gp41 resides within residues 601-613 of the immunodominant loop region  (16) , 98 
which contains hydrophobic side chains and forms a cleft  (23)  .  99 
gC1qR on its own has been shown to suppress the production of HIV-1 in MT-4 and H9 human 100 
T cell lines, and macrophages infected with HIV-1IIIB and HIV-1Ba-L  (24)  Suppression of virus 101 
production is further enhanced when gC1qR is pre-incubated with the target cell lines prior to 102 
HIV-1 challenge, suggesting that interference with viral entry by gC1qR occurs through 103 
interaction with CD4  (24) . gC1qR is known to bind to a range of viral ligands including the 104 
HCV core protein  (25) , Adenovirus core protein V  (26)   EBNA-1  (27)  and Rubella virus 105 
capsid protein  (28) . gC1qR can also act as a receptor for HIV-1 gp41 and target healthy CD4+ T 106 
cells to Natural Killer (NK) cell-mediated lysis  (17) . This bystander effect of autologous killing 107 
occurs through the surface translocation of NKP44L, through activation of PI3K, NADPH 108 
oxidase and p190 RhoGAP.    109 
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Recently, DC-SIGN, C1q and gC1qR on immature DCs have been shown to form a tripartite 110 
complex, with a plausible role in DC differentiation through signaling via the NF-κB pathway  111 
(15) . Given that each of these innate immune proteins (C1q, DC-SIGN and gC1qR) can bind 112 
HIV-1, we set out to dissect the nature of interaction between C1q and DC-SIGN, and examine 113 
how it can impact upon HIV-1 transmission. 114 
MATERIALS AND METHODS 115 
Expression and purification of soluble DC-SIGN and SIGN-R 116 
The pT5T constructs expressing tetrameric and monomeric forms of DC-SIGN and SIGN-R 117 
were transformed into Escherichia coli BL21 (λDE3) (8) . Protein expression was performed in 118 
bacterial culture using Luria-Bertani medium containing 50 µg/ml of ampicillin at 37°C until 119 
OD600 reached 0.7. The bacterial culture was induced with 10mM isopropyl-β-D-thiogalactoside 120 
(IPTG) and incubated for a further 3 h. Bacterial cells (1 litres) were centrifuged at 4500 x g for 121 
15 min at 4°C and cell pellet was treated with 22 ml of lysis buffer containing 100 mM Tris, pH 122 
7.5, 0.5 M NaCl, lysozyme (50µg/ml), 2.5 mM EDTA, pH 8.0 and 0.5 mM 123 
phenylmethylsulfonyl fluoride (PMSF), and left to stir for 1 hour at 4°C. Cells were then 124 
sonicated for 10 cycles for 30 seconds with 2 minute intervals and the sonicated suspension was 125 
spun at 10,000g for 15 min at 4°C. The inclusion bodies, present in the pellet,  were solubilized 126 
in 20 ml of 6 M Urea, 10 mM Tris-HCl, pH 7.0 and 0.01%  β-mercaptoethanol by rotating on a 127 
shaker for 1 h at 4°C. The mixture was then centrifuged at 13,000 x g for 30 min at 4°C and the 128 
supernatant was drop-wise diluted 5-fold with loading buffer containing 25 mM Tris-HCl pH 129 
7.8, 1 M NaCl, and 2.5 mM CaCl2 with gentle stirring. This was then dialysed against 2 litres of 130 
loading buffer with 3 buffer changes every 3 h. Following further centrifugation at 13,000 x g for 131 
15 min at 4°C, the supernatant was loaded onto a Mannan agarose column (5ml; Sigma) pre-132 
equilibrated with the loading buffer. The column was washed with 5 bed volumes of the loading 133 
buffer and the bound protein was eluted in 1 ml fractions using the elution buffer containing 25 134 
mM Tris-HCl pH 7.8, 1 M NaCl, and 2.5 mM EDTA. The absorbance was read at 280 nm and 135 
the peak fractions were frozen at -20. Purity of protein was analyzed by 15% w/v SDS-PAGE. 136 
 137 
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Expression and purification of recombinant wild type globular head modules ghA, ghB and 138 
ghC of human C1q, and their substitution mutants 139 
The recombinant globular head regions of human C1q, ghA, ghB, and ghC modules  (19)  and 140 
their respective mutants  (29)  were expressed in E. coli BL21 as fusion to maltose-binding 141 
protein (MBP). Bacterial cells were grown in 200 ml LB medium containing ampicillin 142 
(100µg/ml) at 37°C, were induced with 0.4 mM IPTG at OD600 of 0.6 for 3 h and then 143 
centrifuged (4500 x g for 15 min). The cell pellet was suspended in 25 ml of lysis buffer (20 mM 144 
Tris-HCl pH 8.0, 0.5 M NaCl, 1 mM EDTA, 0.2% v/v Tween 20, 5% glycerol, 0.1 mM PMSF 145 
and 0.1 mg lysozyme) and incubated at 4°C for 1 h on a rotary shaker. Cell suspension was then 146 
sonicated for 30 seconds with 2 minute gaps for 10 cycles. After centrifugation (13,000 x g for 147 
15 min), the supernatant was diluted 5-fold in buffer I (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 148 
0.2% Tween 20, 1 mM EDTA and 5% glycerol), passed through an amylose resin column (15 149 
ml; New England Biolabs), and then washed with 3 bed volumes of buffer I followed by buffer II 150 
(50 ml of buffer I without Tween 20). The protein was then eluted in 1ml fractions with 10 mM 151 
maltose in 100 ml of buffer II and frozen at -20°C after determining protein concentration and 152 
purity via Nanodrop and 10% w/v SDS-PAGE, respectively. 153 
 154 
Purification of human C1q from plasma 155 
C1q was purified from freshly-thawed plasma as described previously  (19) . Briefly, plasma was 156 
made 5mM EDTA, pH 7.5 and centrifuged to remove aggregated lipids. It was then incubated 157 
with non-immune IgG coupled to CNBr-activated Sepharose (GE Healthcare, UK) for 1 h at 158 
4°C. The plasma with IgG-Sepharose was filtered through a sintered glass funnel, and C1q-159 
bound Sepharose was then washed extensively with 10 mM HEPES, 140 mM NaCl, 0.5 mM 160 
EDTA, pH 7.0. C1q was eluted with CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) buffer 161 
(100 mM CAPS, 1 M NaCl, 0.5 mM EDTA, pH 11). The eluted C1q was then passed through a 162 
HiTrap Protein G column (PierceNet, USA) to remove IgG contaminants and dialyzed against 163 
the washing buffer. 164 
 165 
 166 
 167 
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Expression and purification of human gC1qR 168 
The recombinant mature gC1qR protein containing 74-282 residues was expressed in E. coli 169 
BL21 (λDE3) (Pednekar et al, Frontiers in Immunology, in revision). Bacterial cells were grown 170 
in 250 ml of LB at 37°C until an OD of 0.6 was reached and induced with 0.5mM IPTG. After 3 171 
h, the bacterial cell culture was spun down (4500g 15min). The cell pellet was treated with lysis 172 
buffer (20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1 mM EDTA, 0.2% Tween, 5% glycerol, 0.1mg 173 
lysozyme) and incubated for 1 hour at 4°C with shaking. The cell lysate was then sonicated for 174 
10 cycles at 30 seconds with 2 minute intervals. The lysate was spun down at 13000g for 15min 175 
and the supernatant was collected and dialyzed for 2 h against 20 mM Tris-HCl, pH 7.5. The 176 
dialyzed protein was subjected to ion exchange using a DEAE column and eluted at a peak of 177 
0.45 M NaCl. 178 
Direct Binding ELISA 179 
Microtitre wells were coated overnight at 4°C with DC-SIGN or SIGN-R (5, 2.5, 1.25 and 0.625 180 
µg/well) in carbonate-bicarbonate buffer, pH 9.6) and left overnight at 4°C. Wells were blocked 181 
with 100µl of 2% w/v BSA in PBS for 2 h at 37°C. Following 3 washes with PBS + 0.05% 182 
Tween 20, ghA, ghB, ghC, or its substitution mutants (2.5 µg/100 µl) was added to each well in 183 
the buffer containing 50 mM NaCl, 100 mM Tris-HCl, pH 7.5 and 5 mM CaCl2. MBP (Sigma) 184 
was used as a negative control. The plate was incubated at 37°C for 1.5 h and then at 4°C for 1.5 185 
h. The wells were washed and the bound protein was detected with anti-MBP monoclonal 186 
antibodies in PBS (1:5000, Sigma) followed by rabbit anti-mouse IgG-HRP conjugate (1:5000; 187 
Sigma) for 1 h. The colour was developed using OPD (o-phenylenediamine dihydrochloride, 188 
Sigma) and read at 415 nm. 189 
Competitive ELISA 190 
DC-SIGN and SIGN-R were coated on microtitre wells by overnight incubation at 4°C using 5 191 
µg/well (in 100 µl) in carbonate-bicarbonate buffer pH 9.6. Wells were blocked with 2% BSA in 192 
PBS for 2 h at 37°C. Following washing with PBS + 0.05% Tween, the plate was incubated with 193 
a steady concentration (5 µg/well) of one competing protein (gC1qR) and various concentrations 194 
(5, 2.5, 1.25, 0.625 µg/well) of the second competing protein (ghB) in calcium buffer to give a 195 
total of 100 µl per well. After incubating for 1.5 h at 37°C and 1.5 h at 4°C the wells were 196 
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washed and anti-gC1qR polyclonal antibody (1:1000) in PBS was added and incubated for a 197 
further 1 h at 37°C. Bound protein was detected by Protein A-HRP conjugate (1:5000) and the 198 
colour was developed using o-Phenylenediamine dihydrochloride (OPD). Data was plotted to 199 
determine inhibition values of competitive ligand binding. 200 
 201 
In order to examine if C1q and globular head modules can inhibit binding of DC-SIGN to gp120, 202 
microtitre wells were coated with 250 ng of gp120 (Abcam) in carbonate-bicarbonate buffer and 203 
left overnight at 4ºC. Plate was blocked with 2% w/v BSA in PBS for 2 h at 37°C, followed by 204 
washing three times with PBS + 0.05% Tween 20. Various concentration of ghA, ghB, ghC and 205 
C1q (10, 5, 2.5, 0 µg/ml) were co-mixed with 2.5µg/ml of DC-SIGN, and added to wells in 206 
calcium buffer (100 µl per well). After incubation for 1 h at 37°C and 1 h at 4°C, the wells were 207 
washed again three times using PBS + 0.05% Tween 20. The binding of DC-SIGN to gp120 in 208 
the presence of globular heads and C1q as detected using rabbit anti-DC-SIGN antibody (1:500), 209 
and probed with protein A-HRP conjugate (1:5000). The colour was developed using 3,3′,5,5′-210 
Tetramethylbenzidine (TMB) and read at 450nm spectrophotometrically. 211 
 212 
Western Blotting 213 
Recombinant ghA, ghB and ghC modules (15 µg), in addition to MBP and BSA as negative 214 
control proteins,  were run separately on a 12% SDS-PAGE gel and transferred onto PDVF 215 
membrane for 1 h at 320 mA. Membrane was blocked in 5% non-fat milk (1 h at room 216 
temperature) and 50µg of recombinant DC-SIGN (tetramer) in loading buffer (25 mM Tris-HCl, 217 
pH 7.8, 1 M NaCl, 2.5 mM CaCl2) was added and incubated overnight at room temperature. The 218 
blot was washed three times for 10 min each in PBS containing 0.05% Tween 20 and then 219 
incubated with anti-DC-SIGN (1:1000) polyclonal antibody (ProSci) in 1% non-fat milk (2 h at 220 
37°C). Following subsequent washes, the membrane was incubated with Protein A-conjugated 221 
HRP (1:1000) (1h at room temperature). The blot was developed using 3, 3′-Diaminobenzidine 222 
(Sigma D7679) (DAB) as a substrate. 223 
 224 
 225 
 226 
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Fluorescent microscopy 227 
Binding of C1q globular head modules to DC-SIGN expressed on HEK cells 228 
DC-SIGN expressing HEK 293 (DC-HEK) cells, as reported by Lang et al (30)  were grown in 229 
DMEM-F12 (Life technologies, UK) containing 10% v/v FCS and blasticidin (5µg/ml) (Gibco). 230 
The cells were grown on 13mm glass cover slips till a monolayer of cells was formed, and then 231 
incubated with 15µg/ml of recombinant ghA, ghB and ghC (MBP as a negative control) 232 
separately in serum free medium and left to incubate for 30 min in 37°C. Cells were washed with 233 
PBS and fixed using 4% v/v Paraformaldehyde (PFA) for 10 min, rinsed again with PBS three 234 
times, and then blocked with 5% FCS for 30 min. The slides were incubated for 30 min with 235 
mouse anti-MBP antibody to detect MBP fusion proteins and rabbit anti-DC-SIGN antibody to 236 
reveal expression of DC-SIGN in DC-HEK cells. After three washes for 30 min each and 237 
incubation with secondary antibodies: Alexa Fluor 568 conjugated goat-anti-mouse antibody 238 
(Thermo Fisher) and Alexa Fluor 488 conjugated goat anti-rabbit antibody (Abcam) for 30 min, 239 
the slides were then washed in PBS, mounted and observed under Leica DM4000 Fluorescent 240 
microscope using Leica Application Suite. 241 
HIV-1 transfer assay with DC-HEK cells and PBMC 242 
Pooled Peripheral Blood Mononuclear Cells (PBMCs) (HiMedia Laboratories, India) were 243 
cultured in RPMI 1640 medium (Sigma Aldrich) containing 10% FBS, 1% Penicillin-244 
Streptomycin (Complete RPMI medium), and stimulated with 5 µg/ml phytohemaglutinin (PHA) 245 
and 10 U/ml of recombinant-human IL-2 (Gibco) for 24 h. PHA/IL-2 was washed off and 246 
activated PBMCs were cultured further for 3 days in complete RPMI 1640 medium. 247 
DC-HEK cells were grown and maintained in DMEM-F12 (Sigma Aldrich USA) containing 248 
10% FBS and blasticidin (5µg/ml) (Gibco). Cells were sub-cultured every 3 days and those in the 249 
log phase were used for assays. DC-HEK cells were grown in a 12 well plate until 80% 250 
confluence. Indicated concentrations of C1q, ghA, ghB, ghC, gC1qR individually, or in 251 
combination, in medium containing 5mM CaCl2 were added to each well and incubated for 2 h 252 
to allow binding. Excess protein was removed and cells were challenged with 5 ng/ml p24 of 253 
HIV-1 SF-162 strain for 1 h. MBP was added along with the virus as a negative protein control. 254 
Unbound virus was washed off and cells were co-cultured with PHA/IL-2 activated PBMCs for 255 
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24 h to facilitate viral transfer. PBMCs in the supernatant were then separated from the adhered 256 
DC-HEK monolayer and were cultured further for 7 days and viral titre was determined using 257 
HIV-1 p24 antigen ELISA of supernatants collected on day 4 and 7 (XpressBio Life Science 258 
Products, Frederick, MD). That the reduction in p24 levels was not due to cellular death was 259 
confirmed by MTT assay of cultured PBMCs on day 7. 260 
Statistical analysis 261 
Viral transfer experiment data is plotted using Graph-Pad Prism version 5.0 and data has been 262 
analysed for statistical significance using one way ANOVA. P<0.05 was considered as 263 
statistically significant.   264 
RESULTS 265 
Both DC-SIGN and SIGN-R bind to C1q 266 
DC-SIGN and SIGN-R comprising of the entire extracellular domain (ECD) (Figure 1a, c) and 267 
the CRD region alone (Figure 1b, d) alone were expressed in E. coli and affinity-purified on 268 
Mannose-agarose. The CRD regions of DC-SIGN and SIGN-R bound mannose weakly as 269 
majority of the proteins appeared in the flow through. The ECD domains of both DC-SIGN and 270 
SIGN-R bound to mannose with much greater affinity in the presence of Ca2+ and eluted with 271 
EDTA.  Previously, Kang et al have shown that SIGN-R interacts with C1q  (31) . Recently, 272 
work by Hosszu et al revealed that DC-SIGN bound directly to C1q  (15) . Thus, we examined 273 
direct binding of both the tetrameric and monomeric variants of DC-SIGN and SIGN-R with 274 
purified human C1q on microtitre plates. Both DC-SIGN (Figure 2a) and SIGN-R (Figure 3a) in 275 
their tetrameric and monomeric forms were able to bind to C1q in a dose-dependent manner. 276 
Experiment showed a strong binding of the tetramers to C1q when compared to the CRD region 277 
alone, with the ability of C1q to bind nearly 50% more when the α-helical neck was intact. C1q 278 
bound to SIGN-R (Figure 3a) better than DC-SIGN (Figure 2a). The ability of the globular head 279 
modules to bind DC-SIGN was also examined via a far-western blot (Figure 2d), where ghA, 280 
ghB and ghC, run on a SDS-PAGE and transferred on a nitrocellulose membrane, were probed 281 
with soluble DC-SIGN tetramer. ghA and ghB appeared to bind DC-SIGN well compared to the 282 
ghC module. MBP and BSA, used a negative control proteins, did not bind DC-SIGN tetramer. 283 
 284 
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DC-SIGN and SIGN-R neck region is required for efficient binding to C1q and individual  285 
globular head modules 286 
Tetrameric (Figure 2b) and monomeric (Figure 2c) DC-SIGN and SIGN-R (Figure 3b, c) coated 287 
on microtitre wells were probed with ghA, ghB and ghC to examine whether these globular head 288 
modules were able to bind to the extracellular domain and carbohydrate recognition domain 289 
(CRD) with similar avidity. ghA, ghB and ghC bound with much greater affinity to DC-SIGN 290 
and SIGN-R tetramer in comparison to the monomers, indicating that the neck is required for the 291 
individual globular heads to bind efficiently. Like C1q, the ghA, ghB and ghC modules bound 292 
SIGN-R better than DC-SIGN (Figure 3b). 293 
 294 
DC-SIGN and SIGN-R bind preferentially to ghB module 295 
Since C1q bound to DC-SIGN and SIGN-R via its globular head region, as evident from the use 296 
of ghA, ghB and ghC models, we sought to map their specificity for DC-SIGN and DC-SIGN-R 297 
binding (Figure 2b, 3b). When DC-SIGN and SIGN-R were coated on microtitre wells and 298 
probed with ghA, ghB and ghC, all three globular heads bounds DC-SIGN and SIGN-R in a dose 299 
dependent manner indicating that all three heads are capable of binding to the ligands 300 
independently. Furthermore, ghB module was preferential in binding to DC-SIGN (Figure 2b); it 301 
bound much better to DC-SIGN compared to ghA and ghC. In addition, ghB was a better binder 302 
of SIGN-R, as was ghA for SIGN-R (Figure 3b) than DC-SIGN (Figure 2b), compared with the 303 
ghC module. Although binding of ghA, ghB and ghC to the CRD domain only was significantly 304 
lower, the ghB module was still a better binder of DC-SIGN (Figure 2c) and SIGN-R (Figure 3c) 305 
monomers. 306 
The ghA substitution mutants bind differentially to DC-SIGN and SIGN-R 307 
The ability of substitution mutants ArgA162Glu and ArgA162Ala to bind to DC-SIGN and SIGN-R 308 
was assessed by ELISA. Both substitution mutants bound DC-SIGN (Figure 4a) and SIGN-R 309 
(Figure 5a) in a dose-dependent manner. SIGN-R was able to interact with ArgA162Glu nearly as 310 
efficiently as it did with the wild-type ghA, showing a reduction in binding of only 15%  (5%) at 311 
the highest concentration of 5µg (Figure 5a). ArgA162Ala, on the other hand, bound SIGN-R with 312 
much less affinity, showing a drop of 27% (Figure 5a). Considering DC-SIGN and SIGN-R are 313 
both highly conserved, ArgA162Glu was able to interact with DC-SIGN weakly than it did with 314 
SIGN-R (Figure 4a, 5a), showing a ~35% reduced binding as opposed to ~5% (seen with SIGN-315 
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R.) The mutant ArgA162Ala bound DC-SIGN in a similar manner as it did to its homologue 316 
SIGN-R showing a reduced binding of ~25% (Figure 4a). 317 
ghB substitution mutants bind differentially to DC-SIGN and SIGN-R  318 
Using ELISA, we examined the ability of DC-SIGN to bind to the ghB substitution mutants 319 
ArgB114Gln, ArgB114Ala, ArgB163Glu, ArgB163Ala, ArgB129Ala, ArgB129Glu, HisB117Asp, 320 
TyrB175Leu and LeuB136Gly  (29) . All the ghB substitution mutants bound DC-SIGN (Figure 4b) 321 
and SIGN-R (Figure 5b) in a dose dependent manner. Substituting ArgB114 to Gln and Ala 322 
resulted in a reduction of ~50% in the case of DC-SIGN (Figure 4b) and SIGN-R binding 323 
(Figure 5b), suggesting that the Arg residue at this position plays an important role in the C1q-324 
DC-SIGN/SIGN-R interaction (Table 1, 2).  325 
 326 
Substituting the ghB mutant ArgB129 with Glu and Ala caused a slight reduction of ~20% binding 327 
with DC-SIGN (Figure 4b) and up to ~40% with SIGN-R (Figure 5b). When ArgB163 was 328 
replaced with the negatively charged Glu, its affinity for DC-SIGN and SIGN-R was reduced by 329 
50%  and 35%, respectively (Figure 4b, 5b) (Table 1, 2); substitution with Ala resulted in 30% 330 
reduction for DC-SIGN (Figure 4b) and increase by 20% for SIGN-R (Figure 5b) (Table 1.2). A 331 
greater reduction in DC-SIGN and SIGN-R binding of ~60% was observed for the ghB mutant 332 
HisB117 substituted for Asp.  For the ghB module, TyrB175 substitution to Leu had the most 333 
significant effect, showing a dramatic decrease of up to 90% in binding to DC-SIGN as well as 334 
SIGN-R at a concentration of 0.625µg, this is not surprising due to its role in stabilizing the 335 
gC1q domain. 336 
 337 
Residue Leu136 on ghB, important for IgG binding, is also involved in DC-SIGN binding  338 
Using a series of globular head single residue substitution mutants  (29) , we sought to examine 339 
which residues in the ghB chain offered complementary binding sites for DC-SIGN. Since 340 
LeuB136 and TyrB175 residues are considered important in maintaining the gC1q structure as well 341 
as for IgG binding  (32) , we used LeuB136 substituted for Glu and TyrB175 substituted for Leu in 342 
direct- binding ELISA. LeuB136Gly showed ~50% less binding to DC-SIGN at the highest 343 
concentration (Figure 4b), suggesting that DC-SIGN and IgG binding sites on C1q (ghB) are 344 
overlapping.  345 
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The contributions of ghC substitution mutants to DC-SIGN binding 346 
The substitution mutants His101Ala, Arg156Glu and Leu170Glu bound to DC-SIGN in a dose-347 
dependent manner (Figure 4c). In fact, replacing Leu170 with Glu of the ghC chain reduced 348 
binding to DC-SIGN with a decrease in ~25% at the highest concentration. The ghC mutants 349 
His101Ala reduced binding by 10%, suggesting that the contributions of His101 and Leu170 are 350 
comparable in the DC-SIGN-C1q interaction. The ghC substitution mutants also bound to SIGN-351 
R in a dose-dependent manner.  352 
The mutants His101Ala appeared to show ~10% better binding to SIGN-R with compared to wild 353 
type, whereas Leu170Glu and Arg156Glu showed reduced binding by up to 25% at the highest 354 
concentration of 5 µg of SIGN-R (Figure 5c) (Table 2) 355 
 356 
gC1qR and ghB compete for the same binding site on DC-SIGN 357 
In view of the recent report of gC1qR, C1q and DC-SIGN forming a trimeric complex on 358 
immature DCs  (15) , we examined whether DC-SIGN has complementary and overlapping 359 
binding site for C1q and gC1qR. We have recently mapped the gC1qR binding site on ghA, ghB 360 
and ghC (Pednekar et al, in revision). Since ghB was found to be the preferential binder of DC-361 
SIGN, ghB modules were tested in a competitive assay. When different concentrations of ghB 362 
and a constant concentration of gC1qR were challenged against DC-SIGN, probing with anti-363 
gC1qR polyclonal antibody revealed that with decreasing concentration of ghB, more gC1qR 364 
was able to bind to solid-phase DC-SIGN (Figure 6a), thereby implying an overlapping binding 365 
site between the proteins. 5µg of DC-SIGN and 5µg of gC1qR were able to bind efficiently, 366 
showing an OD of 1 (data not shown); this binding appeared to be drastically reduced when 5µg 367 
of gC1qR was allowed to compete with 5µg of ghB.  368 
 369 
C1q, ghA, ghB, ghC inhibit the binding of DC-SIGN to gp120 370 
C1q, ghA, ghB and ghC were able to inhibit the binding of DC-SIGN to immobilized gp120 in a 371 
dose dependent manner. The highest concentration of C1q, ghA, ghB, and ghC were able to 372 
significantly compete out the binding of DC-SIGN (Figure 6b). 373 
 374 
 375 
 376 
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The ghA, ghB, and ghC modules bind to cell surface expressed DC-SIGN 377 
The binding of globular head modules to DC-SIGN was also performed using HEK 293 cells 378 
expressing DC-SIGN on the cell surface. The surface expression of DC-SIGN on DC-HEK cells 379 
was first confirmed with antibodies against DC-SIGN. To confirm the binding of individual 380 
globular head modules to DC-SIGN on DC-HEK cells, ghA, ghB and ghC fused with MBP were 381 
added to the DC-HEK cells (Figure 7). Incubation of the globular head modules and probing 382 
with anti-MBP monoclonal antibodies showed that each globular head module bound on the 383 
surface of DC-HEK cells co-localizing with DC-SIGN expressed on DC-HEK cells unlike MBP 384 
(Figure 7). This shows that globular heads interacted with DC-SIGN via head region not via 385 
MBP. 386 
C1q inhibits DC-SIGN mediated transfer of HIV-1 to PBMC in culture 387 
Since CD4+ T cells and macrophages are the main cells targeted by HIV-1, we looked at the 388 
potential of C1q, ghA, ghB, ghC, and gC1qR to modulate DC-SING-mediated transfer of HIV-1 389 
to activated PMBCs. As shown in Figure 8a, C1q considerably inhibited viral transfer to PBMCs 390 
in a dose-dependent manner on day 4 and 7. The globular head modules, ghA, ghB and ghC, 391 
surprisingly did not interfere with HIV-1 transfer, neither individually nor collectively, when 392 
compared to untreated or MBP-treated control, suggesting that the collagen region of C1q, 393 
and/or its multivalency of the gC1q domains are likely requirement for enforcing inhibitory 394 
properties. Addition of MBP in the Control wells did not significantly affect the p24 levels in 395 
comparison with untreated controls (data not shown). Furthermore, during the assay period, 396 
cellular viability was not affected by any of the protein treatments, suggesting that differences in 397 
the infectivity were not due to cell death.   398 
 399 
We further examined the involvement of gC1qR with DC-SIGN in HIV-1 infection transmission 400 
(Figure 8b). gC1qR has previously been shown to inhibit CD4-gp120 interaction in HIV-1 401 
isolates. It has also been recognized as a receptor on CD4+ T cells that gp41 engages with in 402 
order to cause death of bystander CD4+ T cells. We wanted to determine the role of gC1qR in 403 
DC-SIGN mediated infection with or without C1q. Figure 8b shows that gC1qR alone did not 404 
mediate viral transfer through DC-SIGN but significantly promoted viral transfer in the presence 405 
of C1q as well as the three globular head modules together for up to 7 days. This suggests that 406 
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the tripartite interaction between C1q, gC1qR and DC-SIGN enhances DC-SIGN mediated viral 407 
transfer. Thus, association of these proteins on DCs may actually promote HIV-1 infection. In 408 
addition, involvement of gC1qR in the tripartite complex is likely to negate the protective effect 409 
of C1q. 410 
 411 
DISCUSSION 412 
The role of complement in HIV-1 pathogenesis is well-documented. Complement-opsonized 413 
HIV-1 causes enhanced viral infection of CD4+ T cell lines  (33) , PBMCs, monocytes and 414 
macrophages  (34) . DC-SIGN on the surface of immature DCs is involved in the capture of C3 415 
opsonized R5 and X4 tropic HIV, and enhanced transmission to T cells  (35) . C1q can bind to 416 
gp41 directly in an antibody-independent manner and activate the classical pathway  (16) ; 417 
however, this leads to an enhanced infection of complement receptor bearing cells  (36) . To 418 
escape complement mediated destruction, HIV-1 uses follicular DCs as a viral reservoir  (37) , 419 
following its internalization via CR2, and remain within its protective recycling endosome.  420 
Following emergence from the endosome to the cell surface, HIV-1 infects follicular T cells 421 
through CD4. HIV-1 opsonized with C3b interacts with CR1 on erythrocytes with factor I 422 
dissociating erythrocytes from this complex and converting C3b to iC3b and C3d. C3d opsonized 423 
HIV-1 is then able to bind to CR2 on B cells  (38) . In this study, we have examined involvement 424 
of C1q in a complement-independent interaction with HIV-1 via DC-SIGN. 425 
C1q is a charge pattern recognition protein that binds to a variety of ligands via its gC1q domain  426 
(19) . Following its ability to interact with SIGN-R  (31) , Hosszu et al recently have shown that 427 
C1q also recognizes a peptide derived from its homologue DC-SIGN  (15) . In the current study, 428 
we made use of the availability of recombinant individual globular head modules of C1q (ghA, 429 
ghB and ghC) and its substitution mutants to establish that C1q binds DC-SIGN (and DC-430 
SIGNR) via its gC1q domain.  431 
Structure-function studies have demonstrated that the CRD region of DC-SIGN is the specific 432 
site for ligand binding and only functions in the presence of the neck region within the ECD  (12) 433 
. We performed a series of binding experiments involving both the tetrameric forms of DC-SIGN 434 
and SIGN-R (comprising of the extracellular domain and CRD region) as well as the monomeric 435 
forms, which only consist of the CRD region. We asked the question whether DC-SIGN and 436 
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SIGN-R binding sites for C1q (and its gC1q domain) lies within their CRD region, or the α-437 
helical neck region also plays an important role in these interactions. Both proteins have an 438 
increased affinity for glycoproteins containing high mannose oligosaccharides, such as mannan  439 
(39) , gp120  (10)  and ICAM-3  (40) , via the CRD region. Here, individual globular head 440 
modules bound better to the tetrameric forms of DC-SIGN and SIGN-R as opposed to just the 441 
CRD region alone, indicating that the neck region, and hence, multimerization is needed to 442 
facilitate C1q binding. The neck region of DC-SIGN and SIGN-R interestingly differ most in 443 
their α helical structures  (8)   as the 23 amino acid repeats only show the first half of each repeat 444 
presenting a pattern of hydrophobic residues spaced at intervals, a feature that is abundant in 445 
most dimeric and trimeric coiled-coils  (41) .  446 
We also found that the ghB module bound better to DC-SIGN and SIGN-R.  Previous studies 447 
have identified ghB as a key module of the gC1q domain in binding to IgG, PTX3 and CRP  (42, 448 
43) . Interestingly, C1q and ghB bound SIGN-R better than DC-SIGN, given 77% sequence 449 
similarity. We also expressed and purified globular head mutants  (29)  where single amino acid 450 
residues were substituted in order to localize key residues involved in C1q interaction with its 451 
various ligands. These mutants were designed based on the crystal structure and are the residues 452 
known to be important in binding to various C1q ligands  (42) . It appears that IgG and DC-453 
SIGN binding sites on ghB are overlapping and shared since Lys136 and Tyr175 on ghB, which 454 
have been previously shown to be important for binding to IgG  (29)  and for gC1q assembly  455 
(44) . We also examined the roles of Arg114, Arg129 and Arg163 of the ghB module since Arginine 456 
residues have previously been shown to be important for the C1q-IgG interaction  (45) . 457 
Moreover, Hosszu et al have reported that C1q binds DC-SIGN via its IgG binding site. Our 458 
results highlighted the significance of Arg114 in C1q interaction with DC-SIGN and SIGN-R 459 
(Figure 4b, 5b). Substituting Arg114 with the polar residue Glutamine and hydrophobic residue 460 
Ala led to ~80% reduction, highlighting a very important role for Arginine114 of B chain in C1q-461 
DC-SIGN interaction. In addition, Tyr175 appears critical for C1q interaction with DC-SIGN and 462 
SIGN-R (Figure 4b, 5b); the binding analysis revealed a dramatic reduction (82% for DC-SIGN  463 
and 90% for SIGN-R following substitution of Tyr with Leu. This is not the first time Tyr175 has 464 
been shown to be a critical residue in gC1q binding  (32) . Gadjeva et al have shown that this 465 
residue mainly constitutes C1q binding to IgM. Overall, our binding studies suggest that Tyr175 466 
and Arg114 of ghB are critical for the C1q-DC-SIGN and C1q-SIGN-R. 467 
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The known dual roles of DC-SIGN as a facilitator of adaptive immune response as well as 468 
promoter of HIV-1 infection prompted us to examine if innate immune soluble factors such as 469 
C1q and gC1qR can potentially modulate viral transmission via DC-SIGN  (46) , similar to 470 
reports involving CD4+ T cells  (47)  and a lectin drug GRFT (Griffithsia) isolated from the red 471 
algae  (48) . We also included DC-SIGN-R (DC-SIGN-Related), a homolog of DC-SIGN, in our 472 
study. DC-SIGN-R is expressed on endothelium including liver sinusoidal  (49) , lymph node 473 
sinuses and placental capillary  (8) . DC-SIGN-R can bind ICAM-3 as well as gp120 to facilitate 474 
HIV-1 viral infection  (49) . As a receptor for bacterial dextrans  (50) and capsular pneumococcal 475 
polysaccharide (CPS) of S. pneumoniae, DC-SIGN-R can cause proteolysis of C3  (31) . DC-476 
SIGN-R is shown to be highly expressed by spleen marginal zone macrophages (MZM) and 477 
lymph node macrophages  (51). SIGN-R1 in MZM interacts with C1q in the spleen and enhances 478 
apoptotic cell clearance via activation of the classical pathway  (52) .  479 
The transmembrane envelope gp41 protein of HIV-1 is known to interact with C1q  (53)   480 
through its A chain  (19) , leading to complement activation but no viral lysis  (54) . Instead, the 481 
virus is transmitted to complement receptor bearing cells such as macrophages and CD4+ T cells 482 
allowing infection to take place  (36, 53, 55, 56) . HIV-1 infected CD4+ T cells can activate the 483 
classical pathway via shedding of gp120, leading to unmasking of the gp41 epitope 601-613 484 
available for interaction with C1q  (23) . C1q is also involved in a range of processes 485 
independent to its complement functions  (57, 58) , including DC differentiation  (59) . C1q, 486 
along with its globular head receptor gC1qR and DC-SIGN can co-localize on the surface of 487 
blood precursor DCs to promote DC differentiation  (15) . gC1qR, a multi-functional pathogen 488 
recognition receptor  (60, 61) , can also interact with gp41 of HIV-1  (17)  on uninfected CD4+ T 489 
cells and upregulate NK cell ligand NKP44-L, rendering healthy CD4+ T cells susceptible to NK 490 
cell lysis. Since DC-SIGN is a receptor for HIV-1 through its binding to gp120, it is interesting 491 
that it co-localizes with C1q and gC1qR, the two proteins, also known for HIV-1 binding and 492 
transmission of the viral infection. Such association forming a tri-molecular unit on the target 493 
cell surface may create a vehicle that promotes pathogen entry and immunosuppression  (15) .  494 
 495 
We wanted to examine if C1q-DC-SIGN interaction modulated HIV-1 transfer. We found that 496 
full length C1q, but not its individual globular heads, suppressed DC-SIGN-mediated HIV-1 497 
transfer to activated PBMCs. Curiously, addition of gC1qR negated the protective effects of C1q 498 
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by enhancing DC-SIGN-mediated viral transfer. gC1qR, as an inhibitor of HIV-1 infection, can 499 
block the interaction between CD4 and gp120 and prevent viral entry  (24) . Since DC-SIGN 500 
binds to gp120 and gC1qR to gp41, both processes which are shown to promote infection, we 501 
can consider that even if gC1qR does interfere with the DC-SIGN-gp120 interaction, its active 502 
binding site for gp41 is still available to facilitate infection. The increased viral transmission of 503 
gC1qR seen when in association with C1q suggests that C1q bound to gC1qR can enhance its 504 
function. It is possible that C1q plays a protective role by blocking access of gp120 to DC-SIGN 505 
(Figure 9). This can happen if C1q shares sharing binding sites on DC-SIGN. The globular 506 
heads, individually or in combination, did not appear to inhibit virus transmission as full length 507 
C1q, suggesting that the Collagen domain of C1q, and/or probably oligomeric form of C1q is 508 
required for the observed inhibitory effect.  509 
 510 
In summary, we found that gC1qR can alter C1q-DC-SIGN interaction in a way that it promotes 511 
viral transfer, thus neutralizing the protective effect of C1q. The tripartite complex involving 512 
DC-SIGN-gC1qR-C1q probably leads to an increase in the distance between DC-SIGN and C1q 513 
that permits DC-SIGN interaction with gp120; this allows DC-SIGN and gC1qR to bind to the 514 
virus with enhanced affinity (Figure 9).  515 
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Table 1 704 
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 720 
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 726 
Table 2 727 
 728 
 729 
 730 
 731 
 732 
 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
Bindings of globular head modules and its 
mutants with DC-SIGN (% binding ± SD) 
ghA 100.00 ±0.0 
R162A 77.71 ±8.85 
R162E 66.41 ±2.38 
ghB 100.0 ± 23.62 
R129E 93.91 ± 8.34 
R129A 75.05 ± 7.22 
R163A 68.76 ± 12.78 
R114A 57.37 ± 4.45 
R114Q 52.46 ± 1.94 
R163E 48.33 ± 8.89 
L136G 47.74 ± 9.17 
T175L 37.92 ± 7.50 
H117D 36.35 ± 10.28 
ghC 100.00±0.00 
R156E 101.41±0.27 
H101A 90.20±2.27 
L170E 78.32±1.47 
Bindings of globular head modules and its 
mutants with SIGN-R (% binding ± SD) 
ghA 100.00 ±0.00 
R162E 94.78 ±15.08 
R162A 73.17 ±9.54 
ghB 100.00 ± 0.00 
R129E 136.70 ± 21.82 
R163A 119.68 ± 30.09 
R129A 92.55 ± 2.26 
R163E 65.69 ± 4.89 
R114A 61.44 ± 0.38 
L136G 53.99 ± 1.88 
R114Q 50.27 ± 3.39 
H117D 40.96 ± 2.26 
T175L 37.23 ± 1.50 
ghC 100.00±0.00 
H101A 112.60±2.86 
L170E 79.81±20.40 
R156E 75.77±4.62 
25 
 
FIGURE LEGENDS 749 
 750 
Figure 1: SDS-PAGE under reducing conditions (12% v/v) showing purified fractions of soluble 751 
DC-SIGN tetramer (a), DC-SIGN Monomer (b), SIGN-R tetramer (c), and SIGN-R monomer 752 
(d), following purification by Mannose-Agarose affinity chromatography. 753 
 754 
Figure 2. Interaction of C1q, ghA, ghB and ghC with DC-SIGN tetramer and monomer. (a) 755 
Microtitre wells coated with different concentrations (5, 2.5, 1.25, 0.625 µg/well) of DC-SIGN 756 
Tetramer or Monomer were probed with 2 µg/well of C1q. Bound C1q was detected with anti-757 
C1q polyclonal antibodies (1:1000 in PBS) and Protein A HRP conjugate (1:1000 in PBS). BSA 758 
was used as a negative control protein. (b) Binding of ghA, ghB and ghC to DC-SIGN Tetramer 759 
and DC-SIGN Monomer involved coating a range of concentrations of the respective proteins on 760 
microtitre wells, which were then incubated with a fixed concentration of ghA, ghB, ghC and 761 
MBP (2.5 µg/well in 5mM CaCl2 buffer) at 37ºC. Binding was detected using anti-MBP 762 
monoclonal antibodies (1:5000 in PBS) and then rabbit anti-mouse IgG-HRP (1:5000 in PBS). 763 
(d) Far western blot to show DC-SIGN tetramer binding to membrane-bound ghA, ghB and ghC: 764 
15µg of ghA, ghB and ghC (BSA and MBP as negative control proteins) were run on a 12% 765 
SDS-PAGE gel, and then transferred on to nitrocellulose membrane. The blot was incubated 766 
with 50µg of DC-SIGN in PBS overnight at room temperature. The bound DC-SIGN protein was 767 
detected using anti-DC-SIGN polyclonal antibodies and Protein A HRP conjugate. Bands were 768 
developed using DAB tablets dissolved in water.    769 
 770 
Figure 3: Interaction of C1q, ghA, ghB and ghC with SIGN-R tetramer and monomer. (a) 771 
ELISA to examine binding of C1q to SIGN-R Tetramer and SIGN-R Monomer: SIGN-R 772 
Tetramer or Monomer were coated at different concentrations, followed by addition of 2µg/well 773 
of C1q. Bound C1q was probed with anti-C1q polyclonal antibodies (1:1000 in PBS) and Protein 774 
A HRP (1:1000 in PBS), and the colour was developed using OPD.  (b) Binding of ghA, ghB 775 
and ghC to SIGN-R Tetramer and (c) SIGN-R Monomer: Different concentrations of SIGN-R 776 
Tetramer (b) and SIGN-R Monomer (b) were coated on microtitre wells in carbonate buffer and 777 
incubated overnight at 4ºC and then incubated with ghA, ghB, ghC and MBP (2.5µg/well in 778 
5mM CaCl2 buffer). Binding was detected using anti-MBP monoclonal antibody and rabbit anti-779 
mouse IgG-HRP conjugate. 780 
 781 
Figure 4: Binding of globular head substitution mutants to DC-SIGN: Different 782 
concentrations of DC-SIGN tetramer were coated on microtitre wells in carbonate buffer 783 
overnight at 4ºC. Wells were then incubated with 2.5µg/well (in CaCl2) of recombinant globular 784 
head wild type and mutant proteins and probed with anti-MBP monoclonal antibody and rabbit 785 
anti-mouse IgG-HRP conjugate, as described earlier. Per cent binding was calculated for each 786 
mutant using binding of the wild type globular head module as 100%. (a) Binding of ghA, ghA-787 
R162E and ghA-R162A to DC-SIGN; (b) Binding of ghB mutants ghB- L136G, ghB-T175L, 788 
ghB- R114Q, ghB-R114A, ghB-R163A, ghB-R163E, ghB-R129E, ghB-R129A and ghB-H117D 789 
to DC-SIGN; (c) Binding of ghC mutants ghC-R156E, ghC-L170E and ghC-H101A to DC-790 
SIGN. 791 
 792 
 793 
 794 
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Figure 5: Binding of globular head substitution mutants to SIGN-R: Different 795 
concentrations of SIGN-R tetramer were coated on microtitre wells in carbonate buffer overnight 796 
at 4ºC and then incubated with 2.5µg/well of recombinant globular head wild type and mutant 797 
proteins and probed with anti-MBP monoclonal antibody and rabbit anti-mouse IgG-HRP 798 
conjugate. % binding was calculated for each mutant using binding of the wild type globular 799 
head module as 100%. (a) Binding of ghA, ghA-R162E and ghA-R162A to SIGN-R; (b) Binding 800 
of ghB mutants ghB- L136G, ghB-T175L, ghB- R114Q, ghB-R114A, ghB-R163A, ghB-R163E, 801 
ghB-R129E, ghB-R129A and ghB-H117D to SIGN-R; (c) Binding of ghC mutants ghC-R156E, 802 
ghC-L170E and ghC-H101A to SIGN-R. 803 
 804 
Figure 6: Competitive ability of ghA, ghB and ghC for interaction with DC-SIGN in the 805 
presence of gC1qR and gp120. (a) ELISA to assess whether gC1qR and ghB directly compete 806 
for the same binding site on DC-SIGN:  DC-SIGN was coated at 5µg/well overnight at 4oC. 807 
Wells were blocked with 2% BSA in PBS for 2 hours at 37º. 5µg/well of gC1qR and different 808 
concentrations of ghB (5, 2.5, 1.25, 0.625µg/well) were added in buffer containing 5mM CaCl2. 809 
Incubation was carried out at 37º for 1.5 hours and 4º for 1.5 hours. Following repeated washes, 810 
bound gC1qR was probed using rabbit anti-gC1qR polyclonal antibodies (1:1000) and Protein A-811 
HRP (1:1000). Colour was developed using OPD substrate; (b) Competition between DC-SIGN 812 
tetramer and C1q globular head modules to bind solid-phase gp120. Microtitre wells were coated 813 
with 250 ng of gp120. Various concentrations of ghA, ghB, ghC, and C1q and constant 2.5ug/ml 814 
of DC-SIGN were incubated at 37°C for 1 h and then at 4°C for 1 h. The binding of DC-SIGN to 815 
gp120 in the presence of globular heads or C1q was detected using rabbit anti-DC antibody 816 
(1:500), probed with PA HRP (1:5000). 100% binding was taken of DC-SIGN alone binding to 817 
gp120.  818 
 819 
Fig 7: In vitro binding of Globular heads modules to DC-SIGN expressed on HEK cells: 820 
DC-SIGN expressing HEK cells (DC-SIGN cells) were incubated with recombinant globular 821 
head modules (ghA, ghB, ghC) and MBP as control for 30 mins at 37°C. DC-HEK cells were 822 
fixed with 4% PFA, washed and blocked with 5% FCS, and probed with mouse anti MBP 823 
antibody to detect the presence of MBP fused globular head modules and rabbit anti DC-SIGN to 824 
detect DC-SIGN expressed on the cells. Goat anti-mouse secondary antibody conjugated with 825 
Alexa Fluor 568 was used to detect binding of globular heads to DC-SIGN visualized using goat 826 
anti-rabbit IgG conjugated with Alexa Fluor 488 antibody. Scale bar 20µm.  827 
Figure 8: HIV transfer assay mediated by DC-SIGN 828 
HEK/DC-SIGN cells were grown in a 12 well-plate to form a confluent layer. Different 829 
concentrations of proteins were added to the cells and incubated for 2 hours for binding. 830 
Unbound proteins were removed and cells were challenged with 2.5ng/ml p24 of HIV-1 (SF-2 831 
strain) for 1 hour. Unbound virus was washed off and cells were co-cultured with PHA-activated 832 
PBMCs for 24 hours. PBMCs were separated from the DC-HEK monolayer and cultured 833 
separately for 7 days to determine viral titre of the supernatants collected on day 4 and day 7. (a) 834 
C1q, ghA, ghB, ghC and ghABC; (b) gC1qR in presence of C1q, ghA, ghB, ghC and ghABC. 835 
Data represents Mean ± SD. P<0.05 is considered significant. * and # indicate statistical 836 
significance in comparison untreated controls of day 4 and day 7, respectively.  837 
 838 
 839 
 840 
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Figure 9.  Diagrammatic model explaining the possible implications of the tripartite 841 
molecular interplay between DC-SIGN, C1q and gC1qR. (a) By virtue of its ability to bind to 842 
DC-SIGN on the cell surface, C1q is likely to inhibit interaction between DC-SIGN and HIV-1 843 
gp120, resulting in the inhibition of viral transfer. (b) On the DC/Monocyte surface, a tri-844 
molecular receptor complex is formed between gC1qR, C1q and DC-SIGN. Although each of 845 
these molecules can bind the HIV-1 virus independently, we postulate that it is the binding of the 846 
HIV-1 gp-41 to both gC1qR and C1q that initiates the membrane fusion before the final binding 847 
of gp120 to DC-SIGN and/or CD4, eventually allowing the internalization of the virus. It is 848 
possible that HIV-1 interaction with DC/monocytes causes recruitment of gC1qR to the cell 849 
surface, or its secretion, which in turn, can bind to C1q globular heads, thereby neutralizing the 850 
protection offered by C1q.    851 
  852 
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(d) Far Western Blot showing immobilized ghA, ghB and ghC bind soluble DC-SIGN 
tetramer 
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